Trinity Biotech PLC (TRIB)
- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $6.01
- As of
Kresmion compiles this page from TRIB's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
TRINITY BIOTECH PLC (TRIB): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-11-12.
See the full TRIB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TRIB on one page. Preview it with sample data, then open it live with a free account.
Preview the TRIB dossierActive events for TRIB
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 84% of TRIB (2026Q1)
- medium13F: new position
D. E. Shaw & Co., Inc. new position in TRIB
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +125% to TRIB (2026Q1)
- mediumEarnings below estimates
Q2-2024: Missed consensus by 7.7% - EPS $-0.714 vs $-0.663 estimate
- mediumEarnings below estimates
Q4-2024: Missed consensus by 272.5% - EPS $-1.14 vs $-0.306 estimate
FREE, NO ACCOUNT
Every event on TRIB, as it fires
You are seeing 5 of 9 events recorded on TRIB since 2026-05-24.
The five above landed across 2 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, TRIB
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
More data on TRIB
TRIB against its peers
TRIB's operating margin of -34.4% ranks in the 64th percentile of 6 Medical Devices sub-industry peers, fiscal periods ending between 2024-12-31 and 2025-09-30.
| Metric | TRIB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 61.6M USD | 5.3M USD | 94 | 7 |
| Revenue YoY | 8.3% | n/a | n/a | 2 |
| Gross margin | 34.8% | 37.4% | 44 | 7 |
| Operating margin | -34.4% | -94.7% | 64 | 6 |
| Net margin | -51.6% | -88.4% | 56 | 7 |
| Return on equity | n/a | -121.1% | n/a | 7 |
Peers (8): STME, TANAF, WOK, SONX, ICCM, BDMD, BMRA, RMSL. Left out: PMEDF (period gap), NVNO (period gap), USAQ (period gap), TNON (period gap), KLYG (no annual filing), XAIR (period gap), VNRX (period gap), CYDX (no annual filing), VVOS (period gap), AMIX (period gap), INBS (period gap), CSDX (no annual filing), NMTC (no annual filing), AIDX (period gap), BJDX (period gap), IVF (period gap), AEMD (period gap). Fiscal periods ending between 2024-12-31 and 2025-09-30. Every figure is one full fiscal year read from one annual filing (TRIB: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in TRIB on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on TRIB in the last 180 days.
Upstream: SEC EDGAR filings for TRIB
Kresmion, "TRINITY BIOTECH PLC (TRIB) institutional holdings and SEC filings", data as of 2026-11-12, https://kresmion.com/research/TRIB. Upstream data: SEC EDGAR filings for TRIB.
Link to this data (HTML):
<a href="https://kresmion.com/research/TRIB">TRINITY BIOTECH PLC (TRIB) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow TRIB on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to TRIB for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.